Page 2 - நிறுவனம் தெளிவான புள்ளி நரம்பியல் வழிசெலுத்தல் அமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனம் தெளிவான புள்ளி நரம்பியல் வழிசெலுத்தல் அமைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனம் தெளிவான புள்ளி நரம்பியல் வழிசெலுத்தல் அமைப்பு Today - Breaking & Trending Today

ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips
ClearPoint Neuro, Inc.February 18, 2021 GMT
Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™’ Brain Model by 2022
IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a worldwide license and research agreement with Philips, a global leader in health technology, to commercialize the ClearPoint ‘Maestro’ Brain Model. The company expects the first-generation anatomical segment analysis tool to be launched in 2022. ....

United States , Joe Burnett , Jacqueline Keller , Erik Pastink , Company Clearpoint Neuro Navigation System , Clearpoint Neuro Inc , Company Annual Report On Form , Exchange Commission , Applications Of The Company , Company Quarterly Report On Form , Company Smartflow , Program Leader Healthtech Ip Licensing At Philips , Enable Clearpoint , Brain Model , Point Neuro , Maestro Brain , Program Leader Healthtech , Clearpoint Neuro , Philips Brain Model , Clearpoint Neuro Navigation System , Annual Report , Quarterly Report , Vice President , Licensing Agreements , Corporate News , Covid 19 Pandemic ,

ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners

(1)
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoint s Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).
ClearPoint Neuro s Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. ....

United States , Clearpoint Biologics , Kostenloser Wertpapierhandel , Jeremy Stigall , Ernesto Salegio , Company As Vice , Biologics Drug Delivery Development , Company Clearpoint Neuro Navigation System , Clearpoint Neuro Inc , Exchange Commission , Company Annual Report On Form , Clinical Research , Applications Of The Company , Company Quarterly Report On Form , Company Smartflow , Point Neuro , Vice President , Segment Leader Translational , Preclinical Research , Drug Delivery , Clearpoint Neuro Navigation System , Annual Report , Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , தெளிவான புள்ளி உயிரியல் , ஜெர்மி ஸ்டிகல்ல் ,

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint 2.0 Software in Europe

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint 2.0 Software in Europe
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro Navigation System, at Rigshospitalet in Copenhagen, Denmark. The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.
ClearPoint offers a stereotactic system based on MRI localization with an MRI compatible frame. My clear impression, after my first-time experience, is that the system offers superior accuracy of the stereotactic procedure as compared to our standard frame with CT localization, stated Rune Rasmussen, MD, PhD, Head of Stereotactics at Rigshospitalet. W ....

United States , Kostenloser Wertpapierhandel , Matt Rabon , Jacqueline Keller , Company Clearpoint Neuro Navigation System , Clearpoint Neuro Inc , Exchange Commission , Company Annual Report On Form , Applications Of The Company , Company Quarterly Report On Form , Business Development , Company Smartflow , Point Neuro , Clearpoint Neuro Navigation System , Clearpoint System , Rune Rasmussen , Business Development Manager , Annual Report , Quarterly Report , Vice President , Clear Point , ஒன்றுபட்டது மாநிலங்களில் , மேட் ரபன் , ஜாக்குலின் கெல்லரர் , நிறுவனம் தெளிவான புள்ளி நரம்பியல் வழிசெலுத்தல் அமைப்பு , தெளிவான புள்ளி நரம்பியல் இன்க் ,

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
Represents Draw of Additional Proceeds from Petrichor Announced in January 2020
IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financing agreement with Petrichor Healthcare Capital Management (“Petrichor”) and PTC Therapeutics, Inc. The amendment, closed today, provides for an additional $7.5 million strategic investment from Petrichor and improves terms relative to the original conversion price and interest rate. The Company intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts. ....

United States , Harolda Hurwitz , Joe Burnett , Tadd Wessel , Jacqueline Keller , Company Clearpoint Neuro Navigation System , Clearpoint Neuro Inc , Fortress Investment Group , Exchange Commission , Company Annual Report On Form , Therapeutics Inc , Company Quarterly Report On Form , Applications Of The Company , Company Smartflow , Represents Draw , Additional Proceeds , Petrichor Announced , Clearpoint Neuro , Petrichor Healthcare Capital Management , Drug Delivery , Managing Partner , Securities Act , Current Report , Point Neuro , Clearpoint Neuro Navigation System , Healthcare Capital Management ,